Details of the Drug

General Information of Drug (ID: DMPN1TW)

Drug Name
Dofetilide
Synonyms
Dofetilida; Dofetilidum; Tikosyn; Xelide; UK 68798; Dofetilida [INN-Spanish]; Dofetilidum [INN-Latin];Tikosyn (TN); UK 68,798; UK-68798; Dofetilide [USAN:BAN:INN]; Tikosyn, UK68798, Dofetilide; UK-68,798; Dofetilide (JAN/USAN/INN); Beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide; N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide; N-(4-{2-[methyl(2-{4-[(methylsulfonyl)amino]phenoxy}ethyl)amino]ethyl}phenyl)methanesulfonamide; Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl); 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane; 1-MSPMPE
Indication
Disease Entry ICD 11 Status REF
Sinus rhythm disorder BC9Y Approved [1]
Therapeutic Class
Antiarrhythmic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 441.6
Logarithm of the Partition Coefficient (xlogp) 1.8
Rotatable Bond Count (rotbonds) 11
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Absorption
The absorption of drug is more than 90% []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [2]
Bioavailability
96% of drug becomes completely available to its intended biological destination(s) [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 5.2 mL/min/kg [4]
Elimination
64% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 10 hours [4]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.03774 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.36% [4]
Vd
The volume of distribution (Vd) of drug is 3 L/kg []
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Poisoning and toxicity Not Available CYP2D6 OTZJC802 [6]
Sudden cardiac death Not Available KCNQ1 OT8SPJNX [6]
Sudden cardiac death Not Available SCN5A OTGYZWR6 [6]
Sudden cardiac death Not Available KCNE1 OTZNQUW9 [6]
Chemical Identifiers
Formula
C19H27N3O5S2
IUPAC Name
N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide
Canonical SMILES
CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C
InChI
InChI=1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3
InChIKey
IXTMWRCNAAVVAI-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
71329
ChEBI ID
CHEBI:4681
CAS Number
115256-11-6
DrugBank ID
DB00204
TTD ID
D0NW3X
VARIDT ID
DR00724
INTEDE ID
DR0522
ACDINA ID
D00208
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Potassium channel unspecific (KC) TT1VOHK NOUNIPROTAC Modulator [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug and toxin extrusion protein 2 (SLC47A2) DT3TX4H S47A2_HUMAN Substrate [8]
Multidrug and toxin extrusion protein 1 (SLC47A1) DTZGT0P S47A1_HUMAN Substrate [8]
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [9]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Drug Response [6]
Potassium voltage-gated channel subfamily E member 1 (KCNE1) OTZNQUW9 KCNE1_HUMAN Drug Response [6]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Gene/Protein Processing [10]
Potassium voltage-gated channel subfamily KQT member 1 (KCNQ1) OT8SPJNX KCNQ1_HUMAN Drug Response [6]
Sodium channel protein type 5 subunit alpha (SCN5A) OTGYZWR6 SCN5A_HUMAN Drug Response [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dofetilide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Dofetilide and Sotalol. Cardiac arrhythmia [BC9Z] [11]
Moricizine DMOMBJW Major Increased risk of prolong QT interval by the combination of Dofetilide and Moricizine. Cardiac arrhythmia [BC9Z] [11]
Coadministration of a Drug Treating the Disease Different from Dofetilide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Dofetilide and Ivosidenib. Acute myeloid leukaemia [2A60] [12]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Dofetilide and Midostaurin. Acute myeloid leukaemia [2A60] [12]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Dofetilide and Idarubicin. Acute myeloid leukaemia [2A60] [12]
Daunorubicin DMQUSBT Major Increased risk of prolong QT interval by the combination of Dofetilide and Daunorubicin. Acute myeloid leukaemia [2A60] [12]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Dofetilide and Arn-509. Acute myeloid leukaemia [2A60] [12]
Gilteritinib DMTI0ZO Major Increased risk of prolong QT interval by the combination of Dofetilide and Gilteritinib. Acute myeloid leukaemia [2A60] [12]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Dofetilide and Oliceridine. Acute pain [MG31] [12]
Terfenadine DM4KLPT Major Increased risk of prolong QT interval by the combination of Dofetilide and Terfenadine. Allergic/hypersensitivity disorder [4A80-4A8Z] [12]
Tacrine DM51FY6 Moderate Increased risk of ventricular arrhythmias by the combination of Dofetilide and Tacrine. Alzheimer disease [8A20] [12]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Dofetilide and Galantamine. Alzheimer disease [8A20] [12]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Dofetilide and Rivastigmine. Alzheimer disease [8A20] [12]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Dofetilide and Metronidazole. Amoebiasis [1A36] [13]
Ranolazine DM0C9IL Major Increased risk of prolong QT interval by the combination of Dofetilide and Ranolazine. Angina pectoris [BA40] [12]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Ivabradine. Angina pectoris [BA40] [14]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Dofetilide and Bepridil. Angina pectoris [BA40] [12]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Dofetilide and Dronedarone. Angina pectoris [BA40] [12]
Nifedipine DMSVOZT Moderate Decreased metabolism of Dofetilide caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [11]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Dofetilide and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [12]
Hydroxyzine DMF8Y74 Major Increased risk of prolong QT interval by the combination of Dofetilide and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [12]
Promazine DMZAL7W Major Increased risk of prolong QT interval by the combination of Dofetilide and Promazine. Appearance/behaviour symptom [MB23] [12]
Cilostazol DMZMSCT Major Increased risk of prolong QT interval by the combination of Dofetilide and Cilostazol. Arterial occlusive disease [BD40] [12]
Voriconazole DMAOL2S Major Increased risk of prolong QT interval by the combination of Dofetilide and Voriconazole. Aspergillosis [1F20] [12]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Dofetilide and Posaconazole. Aspergillosis [1F20] [12]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Dofetilide and Levalbuterol. Asthma [CA23] [15]
Terbutaline DMD4381 Major Increased risk of prolong QT interval by the combination of Dofetilide and Terbutaline. Asthma [CA23] [16]
Zafirlukast DMHNQOG Moderate Decreased metabolism of Dofetilide caused by Zafirlukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [11]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Dofetilide and Pirbuterol. Asthma [CA23] [16]
Isoetharine DMITSEH Moderate Increased risk of prolong QT interval by the combination of Dofetilide and Isoetharine. Asthma [CA23] [16]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Dofetilide and Salbutamol. Asthma [CA23] [17]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Dofetilide and Formoterol. Asthma [CA23] [16]
Atomoxetine DM5L6HI Major Increased risk of prolong QT interval by the combination of Dofetilide and Atomoxetine. Attention deficit hyperactivity disorder [6A05] [12]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Dofetilide and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [12]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Dofetilide and Desipramine. Attention deficit hyperactivity disorder [6A05] [12]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Dofetilide and Ofloxacin. Bacterial infection [1A00-1C4Z] [12]
Ciprofloxacin XR DM2NLS9 Major Increased risk of prolong QT interval by the combination of Dofetilide and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [12]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Dofetilide caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [11]
Clarithromycin DM4M1SG Major Increased risk of prolong QT interval by the combination of Dofetilide and Clarithromycin. Bacterial infection [1A00-1C4Z] [12]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Dofetilide and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [12]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Dofetilide and Sparfloxacin. Bacterial infection [1A00-1C4Z] [18]
Chloramphenicol DMFXEWT Moderate Decreased metabolism of Dofetilide caused by Chloramphenicol mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [11]
Gemifloxacin DMHT34O Major Increased risk of prolong QT interval by the combination of Dofetilide and Gemifloxacin. Bacterial infection [1A00-1C4Z] [12]
Norfloxacin DMIZ6W2 Major Increased risk of prolong QT interval by the combination of Dofetilide and Norfloxacin. Bacterial infection [1A00-1C4Z] [12]
Capreomycin DMNZBRY Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Capreomycin. Bacterial infection [1A00-1C4Z] [11]
Levofloxacin DMS60RB Major Increased risk of prolong QT interval by the combination of Dofetilide and Levofloxacin. Bacterial infection [1A00-1C4Z] [12]
Moxifloxacin DMU8V4S Major Increased risk of prolong QT interval by the combination of Dofetilide and Moxifloxacin. Bacterial infection [1A00-1C4Z] [12]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Dofetilide caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [11]
Lomefloxacin DMVRH9C Major Increased risk of prolong QT interval by the combination of Dofetilide and Lomefloxacin. Bacterial infection [1A00-1C4Z] [12]
Telithromycin DMZ4P3A Major Increased risk of prolong QT interval by the combination of Dofetilide and Telithromycin. Bacterial infection [1A00-1C4Z] [19]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Dofetilide and Retigabine. Behcet disease [4A62] [12]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Dofetilide and Loperamide. Bowel habit change [ME05] [20]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Dofetilide and Eribulin. Breast cancer [2C60-2C6Y] [12]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Dofetilide and Lapatinib. Breast cancer [2C60-2C6Y] [12]
Tucatinib DMBESUA Moderate Decreased metabolism of Dofetilide caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [11]
Palbociclib DMD7L94 Moderate Decreased metabolism of Dofetilide caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [11]
Tamoxifen DMLB0EZ Major Increased risk of prolong QT interval by the combination of Dofetilide and Tamoxifen. Breast cancer [2C60-2C6Y] [12]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Dofetilide and Toremifene. Breast cancer [2C60-2C6Y] [12]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Dofetilide and Bosutinib. Breast cancer [2C60-2C6Y] [12]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Dofetilide and Grepafloxacin. Bronchitis [CA20] [18]
Iodipamide DMXIQYS Moderate Increased risk of ventricular arrhythmias by the combination of Dofetilide and Iodipamide. Cholelithiasis [DC11] [21]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Dofetilide and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [12]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Dofetilide and Olodaterol. Chronic obstructive pulmonary disease [CA22] [16]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Dofetilide and Vilanterol. Chronic obstructive pulmonary disease [CA22] [15]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Dofetilide and Salmeterol. Chronic obstructive pulmonary disease [CA22] [16]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Dofetilide and Indacaterol. Chronic obstructive pulmonary disease [CA22] [16]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Dofetilide and Arformoterol. Chronic obstructive pulmonary disease [CA22] [16]
Phenylbutazone DMAYL0T Minor Increased metabolism of Dofetilide caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [11]
Oxaliplatin DMQNWRD Major Increased risk of prolong QT interval by the combination of Dofetilide and Oxaliplatin. Colorectal cancer [2B91] [12]
Panitumumab DMQPD1F Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Panitumumab. Colorectal cancer [2B91] [11]
Isoproterenol DMK7MEY Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Isoproterenol. Conduction disorder [BC63] [16]
Bupivacaine DM4PRFC Moderate Increased risk of bradycardia by the combination of Dofetilide and Bupivacaine. Corneal disease [9A76-9A78] [22]
Levobupivacaine DM783CH Moderate Increased risk of bradycardia by the combination of Dofetilide and Levobupivacaine. Corneal disease [9A76-9A78] [22]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Dofetilide and Halothane. Corneal disease [9A76-9A78] [12]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Dofetilide and Propofol. Corneal disease [9A76-9A78] [23]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Dofetilide and Sevoflurane. Corneal disease [9A76-9A78] [12]
Lidocaine DML4ZOT Major Increased risk of prolong QT interval by the combination of Dofetilide and Lidocaine. Corneal disease [9A76-9A78] [11]
Ropivacaine DMSPJG2 Moderate Increased risk of atrioventricular block by the combination of Dofetilide and Ropivacaine. Corneal disease [9A76-9A78] [22]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Dofetilide and Probucol. Coronary atherosclerosis [BA80] [12]
Methadone DMTW6IU Major Increased risk of prolong QT interval by the combination of Dofetilide and Methadone. Cough [MD12] [12]
Clofazimine DMEBOFW Major Increased risk of prolong QT interval by the combination of Dofetilide and Clofazimine. Crohn disease [DD70] [12]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Dofetilide and Mifepristone. Cushing syndrome [5A70] [12]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Dofetilide and Pasireotide. Cushing syndrome [5A70] [12]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Dofetilide and Osilodrostat. Cushing syndrome [5A70] [12]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Dofetilide caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [11]
MK-8228 DMOB58Q Moderate Decreased metabolism of Dofetilide caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [11]
Aprepitant DM053KT Moderate Decreased metabolism of Dofetilide caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [24]
Sertraline DM0FB1J Major Increased risk of prolong QT interval by the combination of Dofetilide and Sertraline. Depression [6A70-6A7Z] [12]
Trimipramine DM1SC8M Major Increased risk of prolong QT interval by the combination of Dofetilide and Trimipramine. Depression [6A70-6A7Z] [12]
Imipramine DM2NUH3 Major Increased risk of prolong QT interval by the combination of Dofetilide and Imipramine. Depression [6A70-6A7Z] [12]
Fluoxetine DM3PD2C Major Increased risk of prolong QT interval by the combination of Dofetilide and Fluoxetine. Depression [6A70-6A7Z] [12]
Nortriptyline DM4KDYJ Major Increased risk of prolong QT interval by the combination of Dofetilide and Nortriptyline. Depression [6A70-6A7Z] [12]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Dofetilide caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [11]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Dofetilide and Escitalopram. Depression [6A70-6A7Z] [12]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Dofetilide and Clomipramine. Depression [6A70-6A7Z] [12]
Trazodone DMK1GBJ Major Increased risk of prolong QT interval by the combination of Dofetilide and Trazodone. Depression [6A70-6A7Z] [12]
Amoxapine DMKITQE Major Increased risk of prolong QT interval by the combination of Dofetilide and Amoxapine. Depression [6A70-6A7Z] [12]
Mirtazapine DML53ZJ Major Increased risk of prolong QT interval by the combination of Dofetilide and Mirtazapine. Depression [6A70-6A7Z] [12]
Protriptyline DMNHTZI Major Increased risk of prolong QT interval by the combination of Dofetilide and Protriptyline. Depression [6A70-6A7Z] [12]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Dofetilide and Doxepin. Depression [6A70-6A7Z] [12]
Maprotiline DMPWB7T Major Increased risk of prolong QT interval by the combination of Dofetilide and Maprotiline. Depression [6A70-6A7Z] [12]
Venlafaxine DMR6QH0 Major Increased risk of prolong QT interval by the combination of Dofetilide and Venlafaxine. Depression [6A70-6A7Z] [12]
Citalopram derivative 1 DMITX1G Major Increased risk of prolong QT interval by the combination of Dofetilide and Citalopram derivative 1. Discovery agent [N.A.] [12]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Dofetilide and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [12]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Dofetilide and Deutetrabenazine. Dystonic disorder [8A02] [12]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Dofetilide and Ingrezza. Dystonic disorder [8A02] [12]
Primidone DM0WX6I Minor Increased metabolism of Dofetilide caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [11]
Oxcarbazepine DM5PU6O Minor Increased metabolism of Dofetilide caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [11]
Stiripentol DMMSDOY Moderate Decreased metabolism of Dofetilide caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [11]
Phenytoin DMNOKBV Major Increased risk of prolong QT interval by the combination of Dofetilide and Phenytoin. Epilepsy/seizure [8A61-8A6Z] [11]
Fosphenytoin DMOX3LB Minor Increased metabolism of Dofetilide caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [11]
Phenobarbital DMXZOCG Minor Increased metabolism of Dofetilide caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [11]
Carbamazepine DMZOLBI Minor Increased metabolism of Dofetilide caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [11]
Diphenhydramine DMKQTBA Moderate Increased risk of prolong QT interval by the combination of Dofetilide and Diphenhydramine. Episodic vestibular syndrome [AB31] [13]
Ethacrynic acid DM60QMR Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Ethacrynic acid. Essential hypertension [BA00] [11]
Bendroflumethiazide DM7EVLC Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Bendroflumethiazide. Essential hypertension [BA00] [11]
Benzthiazide DMQWZ0H Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Benzthiazide. Essential hypertension [BA00] [11]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Dofetilide and Solifenacin. Functional bladder disorder [GC50] [12]
Itraconazole DMCR1MV Major Decreased metabolism of Dofetilide caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [12]
Pentamidine DMHZJCG Major Increased risk of prolong QT interval by the combination of Dofetilide and Pentamidine. Fungal infection [1F29-1F2F] [12]
Clotrimazole DMMFCIH Moderate Decreased metabolism of Dofetilide caused by Clotrimazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [11]
Miconazole DMPMYE8 Moderate Decreased metabolism of Dofetilide caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [13]
Amphotericin B DMTAJQE Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Amphotericin B. Fungal infection [1F29-1F2F] [11]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Dofetilide and Cisapride. Gastro-oesophageal reflux disease [DA22] [12]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Dofetilide and Sunitinib. Gastrointestinal stromal tumour [2B5B] [12]
Acetazolamide DM1AF5U Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Acetazolamide. Glaucoma [9C61] [11]
Methazolamide DM7J2TA Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Methazolamide. Glaucoma [9C61] [11]
Dichlorphenamide DMH7IDQ Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Dichlorphenamide. Glaucoma [9C61] [11]
Sulfinpyrazone DMEV954 Minor Increased metabolism of Dofetilide caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [11]
Triamterene DM2HU9I Moderate Decreased elimination of Dofetilide caused by Triamterene mediated competitive inhibition of renal tubular secretion. Heart failure [BD10-BD1Z] [11]
Chlorothiazide DMLHESP Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Chlorothiazide. Heart failure [BD10-BD1Z] [11]
Furosemide DMMQ8ZG Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Furosemide. Heart failure [BD10-BD1Z] [11]
Amiloride DMRTSGP Moderate Decreased elimination of Dofetilide caused by Amiloride mediated competitive inhibition of renal tubular secretion. Heart failure [BD10-BD1Z] [11]
Bumetanide DMRV7H0 Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Bumetanide. Heart failure [BD10-BD1Z] [11]
Hydroflumethiazide DMVPUQI Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Hydroflumethiazide. Heart failure [BD10-BD1Z] [11]
Torasemide DMXKJ6C Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Torasemide. Heart failure [BD10-BD1Z] [11]
Boceprevir DMBSHMF Moderate Decreased metabolism of Dofetilide caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [11]
Telaprevir DMMRV29 Moderate Decreased metabolism of Dofetilide caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [11]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Dofetilide caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [11]
Rifampin DMA8J1G Minor Increased metabolism of Dofetilide caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [25]
Rifapentine DMCHV4I Minor Increased metabolism of Dofetilide caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [11]
Indinavir DM0T3YH Moderate Decreased metabolism of Dofetilide caused by Indinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [11]
Delavirdine DM3NF5G Moderate Decreased metabolism of Dofetilide caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [11]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Dofetilide caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [11]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Dofetilide and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [12]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Dofetilide caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [11]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Dofetilide and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [26]
Dolutegravir DMCZGRE Major Decreased clearance of Dofetilide due to the transporter inhibition by Dolutegravir. Human immunodeficiency virus disease [1C60-1C62] [11]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Dofetilide and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [27]
Lopinavir DMITQS0 Major Increased risk of prolong QT interval by the combination of Dofetilide and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [12]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Dofetilide and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [12]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Dofetilide caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [11]
Darunavir DMN3GCH Moderate Decreased metabolism of Dofetilide caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [11]
Atazanavir DMSYRBX Moderate Decreased metabolism of Dofetilide caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [11]
Ritonavir DMU764S Moderate Decreased metabolism of Dofetilide caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [11]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Dofetilide caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [11]
Levamlodipine DM92S6N Moderate Decreased metabolism of Dofetilide caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [11]
Diltiazem DMAI7ZV Moderate Decreased metabolism of Dofetilide caused by Diltiazem mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [11]
Amlodipine DMBDAZV Moderate Decreased metabolism of Dofetilide caused by Amlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [11]
Fenoldopam DMFAOKP Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Fenoldopam. Hypertension [BA00-BA04] [11]
Indapamide DMGN1PW Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Indapamide. Hypertension [BA00-BA04] [11]
Trichlormethiazide DMHAQCO Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Trichlormethiazide. Hypertension [BA00-BA04] [11]
Conivaptan DM1V329 Moderate Decreased metabolism of Dofetilide caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [28]
Fludrocortisone DMUDIR8 Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [11]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Dofetilide caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [11]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Dofetilide caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [11]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Polyethylene glycol. Irritable bowel syndrome [DD91] [29]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Dofetilide and Phenolphthalein. Irritable bowel syndrome [DD91] [12]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Dofetilide and Crizotinib. Lung cancer [2C25] [12]
Brigatinib DM7W94S Moderate Increased metabolism of Dofetilide caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [30]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Dofetilide and Ceritinib. Lung cancer [2C25] [12]
PF-06463922 DMKM7EW Moderate Increased metabolism of Dofetilide caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [31]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Dofetilide and Osimertinib. Lung cancer [2C25] [12]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Dofetilide and Selpercatinib. Lung cancer [2C25] [12]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Dofetilide and Lumefantrine. Malaria [1F40-1F45] [13]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Dofetilide and Halofantrine. Malaria [1F40-1F45] [32]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Dofetilide and Chloroquine. Malaria [1F40-1F45] [12]
Quinine DMSWYF5 Major Increased risk of prolong QT interval by the combination of Dofetilide and Quinine. Malaria [1F40-1F45] [12]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Dofetilide and Primaquine. Malaria [1F40-1F45] [12]
Mefloquine DMWT905 Major Increased risk of prolong QT interval by the combination of Dofetilide and Mefloquine. Malaria [1F40-1F45] [12]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Dofetilide and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [12]
Idelalisib DM602WT Moderate Decreased metabolism of Dofetilide caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [11]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Arsenic trioxide. Mature B-cell lymphoma [2A85] [33]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Dofetilide and Vemurafenib. Melanoma [2C30] [12]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Dofetilide and LGX818. Melanoma [2C30] [12]
Danazol DML8KTN Moderate Decreased metabolism of Dofetilide caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [11]
Exjade DMHPRWG Moderate Decreased metabolism of Dofetilide caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [34]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Dofetilide and Panobinostat. Multiple myeloma [2A83] [12]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Dofetilide and Thalidomide. Multiple myeloma [2A83] [13]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Siponimod. Multiple sclerosis [8A40] [13]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Ozanimod. Multiple sclerosis [8A40] [35]
Rifabutin DM1YBHK Minor Increased metabolism of Dofetilide caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [11]
Bexarotene DMOBIKY Minor Increased metabolism of Dofetilide caused by Bexarotene mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [11]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Dofetilide and Romidepsin. Mycosis fungoides [2B01] [12]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Dofetilide caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [11]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Dofetilide and Nilotinib. Myeloproliferative neoplasm [2A20] [12]
Imatinib DM7RJXL Moderate Decreased metabolism of Dofetilide caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [11]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Dofetilide and Dasatinib. Myeloproliferative neoplasm [2A20] [12]
Modafinil DMYILBE Minor Increased metabolism of Dofetilide caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [36]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Dofetilide and Droperidol. Nausea/vomiting [MD90] [12]
Dimenhydrinate DM264B3 Moderate Increased risk of prolong QT interval by the combination of Dofetilide and Dimenhydrinate. Nausea/vomiting [MD90] [13]
Promethazine DM6I5GR Major Increased risk of prolong QT interval by the combination of Dofetilide and Promethazine. Nausea/vomiting [MD90] [12]
Palonosetron DMBHMOX Major Increased risk of prolong QT interval by the combination of Dofetilide and Palonosetron. Nausea/vomiting [MD90] [12]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Dofetilide and Granisetron. Nausea/vomiting [MD90] [12]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Dofetilide and Dolasetron. Nausea/vomiting [MD90] [12]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Dofetilide and Ondansetron. Nausea/vomiting [MD90] [12]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Dofetilide and Entrectinib. Non-small cell lung cancer [2C25] [12]
Chlorthalidone DM4DMBT Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Chlorthalidone. Oedema [MG29] [11]
Metolazone DMB39LO Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Metolazone. Oedema [MG29] [11]
Polythiazide DMCH80F Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Polythiazide. Oedema [MG29] [11]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Dofetilide and Levomethadyl Acetate. Opioid use disorder [6C43] [14]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Dofetilide and Lofexidine. Opioid use disorder [6C43] [12]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Dofetilide and Rucaparib. Ovarian cancer [2C73] [12]
Dextropropoxyphene DM23HCX Major Increased risk of prolong QT interval by the combination of Dofetilide and Dextropropoxyphene. Pain [MG30-MG3Z] [12]
Prilocaine DMI7DZ2 Moderate Increased risk of bradycardia by the combination of Dofetilide and Prilocaine. Pain [MG30-MG3Z] [22]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Dofetilide and Buprenorphine. Pain [MG30-MG3Z] [12]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Dofetilide and Triclabendazole. Parasitic worm infestation [1F90] [12]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Dofetilide and Pimavanserin. Parkinsonism [8A00] [12]
Apomorphine DMX38HQ Major Increased risk of prolong QT interval by the combination of Dofetilide and Apomorphine. Parkinsonism [8A00] [12]
Abametapir DM2RX0I Moderate Decreased metabolism of Dofetilide caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [37]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Dofetilide and Famotidine. Peptic ulcer [DA61] [13]
Lanreotide acetate DMG6ZU4 Moderate Decreased metabolism of Dofetilide caused by Lanreotide acetate mediated inhibition of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [11]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Dofetilide and Macimorelin. Pituitary gland disorder [5A60-5A61] [38]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Dofetilide and Lefamulin. Pneumonia [CA40] [39]
Hydrocortisone DMGEMB7 Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Hydrocortisone. Postoperative inflammation [1A00-CA43] [11]
Ritodrine DM4V6RL Major Increased risk of prolong QT interval by the combination of Dofetilide and Ritodrine. Preterm labour/delivery [JB00] [16]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Dofetilide and Degarelix. Prostate cancer [2C82] [12]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Dofetilide and ABIRATERONE. Prostate cancer [2C82] [12]
Nilutamide DMFN07X Major Increased risk of prolong QT interval by the combination of Dofetilide and Nilutamide. Prostate cancer [2C82] [12]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Dofetilide and Enzalutamide. Prostate cancer [2C82] [12]
Flutamide DMK0O7U Major Increased risk of prolong QT interval by the combination of Dofetilide and Flutamide. Prostate cancer [2C82] [12]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Dofetilide and Relugolix. Prostate cancer [2C82] [12]
Bicalutamide DMZMSPF Major Increased risk of prolong QT interval by the combination of Dofetilide and Bicalutamide. Prostate cancer [2C82] [12]
Alfuzosin DMZVMKF Major Increased risk of prolong QT interval by the combination of Dofetilide and Alfuzosin. Prostate hyperplasia [GA90] [12]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Dofetilide and Levomepromazine. Psychotic disorder [6A20-6A25] [12]
Triflupromazine DMKFQJP Major Increased risk of prolong QT interval by the combination of Dofetilide and Triflupromazine. Psychotic disorder [6A20-6A25] [12]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Dofetilide and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [40]
Sorafenib DMS8IFC Major Increased risk of prolong QT interval by the combination of Dofetilide and Sorafenib. Renal cell carcinoma [2C90] [12]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Dofetilide and Gatifloxacin. Respiratory infection [CA07-CA4Z] [12]
Dexamethasone DMMWZET Minor Increased metabolism of Dofetilide caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [11]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Dofetilide and Quetiapine. Schizophrenia [6A20] [12]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Dofetilide and Mesoridazine. Schizophrenia [6A20] [12]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Dofetilide and Thioridazine. Schizophrenia [6A20] [12]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Dofetilide and Aripiprazole. Schizophrenia [6A20] [13]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Dofetilide and Iloperidone. Schizophrenia [6A20] [12]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Dofetilide and Paliperidone. Schizophrenia [6A20] [12]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Dofetilide and Haloperidol. Schizophrenia [6A20] [12]
Perphenazine DMA4MRX Major Increased risk of prolong QT interval by the combination of Dofetilide and Perphenazine. Schizophrenia [6A20] [12]
Chlorpromazine DMBGZI3 Major Increased risk of prolong QT interval by the combination of Dofetilide and Chlorpromazine. Schizophrenia [6A20] [12]
Clozapine DMFC71L Major Increased risk of prolong QT interval by the combination of Dofetilide and Clozapine. Schizophrenia [6A20] [12]
Trifluoperazine DMKBYWI Major Increased risk of prolong QT interval by the combination of Dofetilide and Trifluoperazine. Schizophrenia [6A20] [12]
Ziprasidone DMM58JY Major Increased risk of prolong QT interval by the combination of Dofetilide and Ziprasidone. Schizophrenia [6A20] [12]
Risperidone DMN6DXL Major Increased risk of prolong QT interval by the combination of Dofetilide and Risperidone. Schizophrenia [6A20] [12]
Olanzapine DMPFN6Y Moderate Increased risk of prolong QT interval by the combination of Dofetilide and Olanzapine. Schizophrenia [6A20] [13]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Dofetilide and Asenapine. Schizophrenia [6A20] [12]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Dofetilide and Pimozide. Schizophrenia [6A20] [14]
Mepivacaine DMH2NMY Moderate Increased risk of atrioventricular block by the combination of Dofetilide and Mepivacaine. Sensation disturbance [MB40] [22]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Dofetilide and Vardenafil. Sexual dysfunction [HA00-HA01] [41]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Dofetilide caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [11]
Larotrectinib DM26CQR Moderate Decreased metabolism of Dofetilide caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [11]
Armodafinil DMGB035 Minor Increased metabolism of Dofetilide caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [36]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Dofetilide and LEE011. Solid tumour/cancer [2A00-2F9Z] [12]
Epirubicin DMPDW6T Major Increased risk of prolong QT interval by the combination of Dofetilide and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [12]
Prednisolone DMQ8FR2 Minor Increased metabolism of Dofetilide caused by Prednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [11]
Cisplatin DMRHGI9 Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Cisplatin. Solid tumour/cancer [2A00-2F9Z] [11]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Dofetilide and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [12]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Dofetilide and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [12]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Dofetilide and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [12]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Dofetilide and Pitolisant. Somnolence [MG42] [12]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Dofetilide and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [12]
Ibutilide DMKXY2R Major Increased risk of prolong QT interval by the combination of Dofetilide and Ibutilide. Supraventricular tachyarrhythmia [BC81] [11]
Adenosine DMM2NSK Major Increased risk of ventricular arrhythmias by the combination of Dofetilide and Adenosine. Supraventricular tachyarrhythmia [BC81] [42]
Zithromax DMN4H2O Major Increased risk of prolong QT interval by the combination of Dofetilide and Zithromax. Syphilis [1A61-1A6Z] [12]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Dofetilide caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [43]
Anagrelide DMSQ8MD Major Increased risk of prolong QT interval by the combination of Dofetilide and Anagrelide. Thrombocytosis [3B63] [12]
Brilinta DMBR01X Moderate Decreased metabolism of Dofetilide caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [11]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Dofetilide and Lenvatinib. Thyroid cancer [2D10] [12]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Dofetilide and Cabozantinib. Thyroid cancer [2D10] [12]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Dofetilide and Papaverine. Tonus and reflex abnormality [MB47] [44]
Tizanidine DMR2IQ4 Major Increased risk of prolong QT interval by the combination of Dofetilide and Tizanidine. Tonus and reflex abnormality [MB47] [12]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Dofetilide and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [40]
Tacrolimus DMZ7XNQ Major Increased risk of prolong QT interval by the combination of Dofetilide and Tacrolimus. Transplant rejection [NE84] [12]
Metformin DM89QE1 Moderate Decreased elimination of Dofetilide caused by Metformin mediated competitive inhibition of renal tubular secretion. Type 2 diabetes mellitus [5A11] [11]
Astemizole DM2HN6Q Major Increased risk of prolong QT interval by the combination of Dofetilide and Astemizole. Vasomotor/allergic rhinitis [CA08] [12]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Dofetilide and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [12]
Bretylium DM1FX74 Major Increased risk of prolong QT interval by the combination of Dofetilide and Bretylium. Ventricular tachyarrhythmia [BC71] [11]
Disopyramide DM5SYZP Major Increased risk of prolong QT interval by the combination of Dofetilide and Disopyramide. Ventricular tachyarrhythmia [BC71] [11]
Mexiletine DMCTE9R Major Increased risk of prolong QT interval by the combination of Dofetilide and Mexiletine. Ventricular tachyarrhythmia [BC71] [11]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Dofetilide and Procainamide. Ventricular tachyarrhythmia [BC71] [11]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Dofetilide and Propafenone. Ventricular tachyarrhythmia [BC71] [11]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Dofetilide and Flecainide. Ventricular tachyarrhythmia [BC71] [11]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Dofetilide and Amiodarone. Ventricular tachyarrhythmia [BC71] [11]
Tocainide DMYNMDP Major Increased risk of prolong QT interval by the combination of Dofetilide and Tocainide. Ventricular tachyarrhythmia [BC71] [11]
⏷ Show the Full List of 291 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Dofetilide 0.125 mg capsule 0.125 mg Oral Capsule Oral
Dofetilide 0.25 mg capsule 0.25 mg Oral Capsule Oral
Dofetilide 0.5 mg capsule 0.5 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2604).
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 FDA Drug Development and Drug Interactions
9 Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug Metab Dispos. 1996 Apr;24(4):447-55.
10 Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.
11 Product Information. Tikosyn (dofetilide) Pfizer US Pharmaceuticals, Atlanta, GA.
12 Canadian Pharmacists Association.
13 Cerner Multum, Inc. "Australian Product Information.".
14 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
15 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
16 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
17 Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
18 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
19 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
20 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
21 Goernig M, Kirmeier T, Krack A, Hartog CS, Figulla HR, Leder U "Iohexol contrast medium induces QT prolongation in amiodarone patients." Br J Clin Pharmacol 58 (2004): 96-98. [PMID: 15206999]
22 Keidar S, Grenadier E, Palant A "Sinoatrial arrest due to lidocaine injection in sick sinus syndrome during amiodarone administration." Am Heart J 104 (1982): 1384-5. [PMID: 7148661]
23 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
24 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
25 Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6. [PMID: 6953748]
26 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
27 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
28 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
29 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
30 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
31 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
32 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
33 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
34 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
35 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
36 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
37 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
38 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
39 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
40 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
41 Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
42 Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
43 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
44 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]